Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of elamipretide injection in China. Welcome to wholesale bulk high quality elamipretide injection for sale here from our factory. Good service and reasonable price are available.
Elamipretide injection is the world's first mitochondrial targeted tetrapeptide drug developed by Stealth BioTherapeutics. Its chemical name is D-Arg-Dmt-Lys-Phe-NH ₂ (Dmt is 2 ', 6' - dimethyltyrosine). The design inspiration for this drug comes from in-depth research on the core role of mitochondrial dysfunction in various diseases, aiming to improve patient prognosis by specifically repairing mitochondrial damage. In 2017, Elamipretide was granted orphan drug status for Barth syndrome (BTHS) by the US FDA, marking its official recognition as a rare disease treatment drug. As of 2025, the drug has not yet received formal approval from the FDA or EMA, but has completed multiple key clinical trials and demonstrated significant efficacy in specific indications.
Elamipretide injection (formerly known as SS-31) is a mitochondrial targeted peptide drug developed by Stealth BioTherapeutics. Its core mechanism is to stabilize the cristae structure and optimize the electron transport chain function by specifically binding to cardiolipin in the inner membrane of mitochondria. Although the drug has not yet received full approval from the US Food and Drug Administration (FDA), it has demonstrated therapeutic potential in multiple clinical fields due to its unique effects of improving mitochondrial energy metabolism and reducing oxidative stress.
Mitochondrial diseases are energy metabolism defects caused by mutations in mitochondrial DNA or nuclear DNA, with clinical manifestations including muscle weakness, exercise intolerance, and multiple system dysfunction. Elamipretide has become the first targeted drug developed for this type of disease mechanism by enhancing ATP synthesis efficiency.
Dry AMD is the leading cause of blindness in the elderly population, characterized by degeneration of photoreceptors caused by mitochondrial dysfunction in retinal pigment epithelium (RPE) cells. Elamipretide targets the repair of energy metabolism in RPE cells through local injection (intravitreal or subconjunctival).
The antioxidant properties of Elamipretide give it a protective effect in ischemia-reperfusion scenarios such as myocardial infarction, stroke, and organ transplantation.
Elamipretide inserts a hydrophobic aromatic ring into the phospholipid bilayer to form a stable complex, thereby: Maintain a highly ordered arrangement of cristae and increase exposure of ATP synthase active sites; Prevent cardiolipin from everting to the outer mitochondrial membrane, inhibit cytochrome c release, and suppress the cascade reaction of apoptosis.
ROS clearance: Directly neutralize superoxide anions (O ₂⁻) and hydrogen peroxide (H ₂ O ₂), reducing the level of lipid peroxidation product MDA; Antioxidant enzyme activation: Upregulation of SOD2 and GPx1 expression, resulting in a long-lasting protective effect.
In the heart failure model, Elamipretide can: Promote the conversion of glucose oxidation to fatty acid oxidation and improve myocardial energy efficiency; Activate the AMPK/PGC-1 α pathway to enhance mitochondrial biogenesis.
Elamipretide, as the first mitochondrial targeted therapy drug, has been partially validated for its clinical value, particularly demonstrating breakthrough potential in the fields of hereditary mitochondrial diseases and dry AMD. However, issues such as heterogeneity in therapeutic efficacy, long-term safety, and cost-effectiveness still need to be addressed through larger scale trials and real-world research.
The core mechanism of action of Elamipretide injection lies in its specific binding to the key phospholipid in the mitochondrial inner membrane, cardiolipin. Phospholipids are the core molecules that maintain the integrity of mitochondrial cristae structure and the function of electron transfer chain (ETC). Their oxidation or remodeling can lead to the breakdown of mitochondrial membrane potential (Δ PSI m) and inhibition of ATP synthesis. Elamipretide binds to the head group of cardiolipin through electrostatic interactions, forming a stable complex that: Stable mitochondrial membrane structure: prevents cardiolipin from migrating from the inner membrane to the outer membrane under oxidative stress, and avoids excessive activation of mitochondrial autophagy. Recovery of membrane potential: In the ischemia-reperfusion injury model, Elamipretide can restore Δ PSI m from 65% of baseline level to 92%, approaching the level of healthy tissue. Inhibition of mPTP opening: By blocking the pathological opening of mitochondrial permeability transition pore (mPTP), reducing cytochrome c release and apoptosis cascade reaction.
Elamipretide reduces reactive oxygen species (ROS) generation through the following pathways: Reduce electronic leakage: At ETC complex III, the drug can reduce the rate of superoxide generation by 41%, thereby reducing the diffusion of ROS into the cytoplasm. Upregulation of antioxidant enzymes: Preclinical data shows that Elamipretide can increase the activity of superoxide dismutase (SOD) in myocardial cells by 2.3 times and the level of glutathione peroxidase (GPx) by 1.8 times. Inhibition of lipid peroxidation: In retinal pigment epithelial cells of patients with dry age-related macular degeneration (dry AMD), drug treatment can reduce the accumulation of 4-hydroxynonenal (4-HNE) by 83%.
The effect of Elamipretide on ATP synthesis is tissue-specific: Skeletal muscle: In BTHS patients, medication can increase the ATP level of the quadriceps muscle from baseline 12.3 μ mol/g to 16.7 μ mol/g (p=0.03), while reducing serum lactate concentration by 41%. Cardiomyopathy: A canine heart failure model showed that long-term use of Elamipretide can improve left ventricular ejection fraction (LVEF) from 28% to 39% and reduce N-terminal pro brain natriuretic peptide (NT proBNP) levels by 57%. Kidney: In a mouse model of ischemia-reperfusion injury, drug treatment restored ATP levels in the renal cortex to 89% of the sham surgery group, while reducing the number of TUNEL positive cells by 62%.
Phase III trial (TAZPOWER): A randomized double-blind crossover trial completed in 2018 included 12 BTHS patients (aged 8-18 years), and the results showed: The primary endpoint: improvement in 6-minute walking distance (6MWD) was not significant (p=0.97), but secondary endpoints such as a 37% decrease in NT proBNP levels (p=0.03) and a 23% increase in skeletal muscle ATP levels (p=0.02) were statistically significant. Open label extension period: 83% of patients reported improved exercise endurance and no serious drug-related adverse events (SAEs) occurred.
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
